OR WAIT null SECS
June 07, 2024
Raphael Townshend, founder and CEO of Atomic AI, speaks on AI’s usefulness in characterizing molecular structure and advancing molecular engineering.
Andrew Carnegie of Inaphaea BioLabs explains the role of a translational CRO and of PDC models in drug discovery.
June 06, 2024
Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
Chemify founder and CEO, Lee Cronin gives insight into the combination of digital chemistry, robotics, and AI in the drug discovery process.
June 05, 2024
Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.
May 17, 2024
Regeneron’s Bari Kowal, senior vice-president, head Development Operations & Portfolio Management, gave insight into how the biopharma industry views the application of AI in R&D.
May 10, 2024
Studies conducted by a team at Oxford Biomedica demonstrated that HIC can be used to effectively separate non-deamidated capsids from deamidated capsids.
May 05, 2024
Digital transformation is allowing for better handling, analysis, and protection of vast data collection.
April 03, 2024
NGS abbreviates drug discovery timelines.
March 18, 2024
In a non-exclusive licensing agreement, Ricoh will have access to ERS Genomics’ CRISPR/Cas9 genome editing technology to create novel disease models.